Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.^1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.^3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.⁶ Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.⁷

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

• Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes
• Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma
• Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses

Faculty

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.^1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.^3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.⁶ Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.⁷

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

• Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes
• Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma
• Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses

Faculty

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.^1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.^3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.⁶ Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.⁷

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

After completing this activity, the participant should be better able to:

• Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes

Faculty

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC., Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.^1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.^3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.⁶ Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.⁷

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

After completing this activity, the participant should be better able to:

• Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes

Faculty

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC., Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Identify patients with EoE using the latest diagnostic recommendations and criteria
• Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
• Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
• Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
• Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

• Recognizing and diagnosing EoE
• Treating EoE as a chronic disease
• Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Identify patients with EoE using the latest diagnostic recommendations and criteria
• Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
• Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
• Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
• Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

• Recognizing and diagnosing EoE
• Treating EoE as a chronic disease
• Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Accredited By

Target Audience

The primary target audience for this activity is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this educational activity, participants should be able to:

• Discuss immunopathogenesis of SLE in relation to novel targeted therapies.
• Translate available and emerging clinical trial data and outcomes into clinically meaningful information for providing care to patients with SLE.
• Explain data about treatment options to patient with SLE.

Activity Description

Immerse yourself in this 60-minute interactive activity to meet a patient with systemic lupus erythematosus (SLE), view concise presentations, and engage in hands-on experience with the content. This activity will highlight the immunopathogenesis of SLE and mechanisms of action of therapies. Additionally, leading clinical experts will review clinical trial data and outcomes, both available and emerging, and translate them into clinically meaningful information for patient care. This activity is one of two in the series, Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Faculty

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

• Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD, and Megan Ragan
• Presenter: Lauren Irving

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Presenter: Sheetal Desai, MD, MSEd

• Advisory Board: Janssen, GlaxoSmithKline
• Speakers Bureau: Janssen, GlaxoSmithKline

Presenter: Bevra H. Hahn, MD

• Advisory Board: Janssen
• Consulting Fee: Aurinia
• Data Safety Monitoring: UCB

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

UEMS-EACCME^®: The UEMS-EACCME^® has an agreement of mutual recognition of AMA PRA Category 1 Credit(s)™. International physicians interested in converting AMA PRA Category 1 Credit(s)™ to EACCME credit should contact the UEMS, https://www.uems.eu/.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Activity Details

Accredited By

Target Audience

The primary target audience for this activity is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this educational activity, participants should be able to:

• Discuss immunopathogenesis of SLE in relation to novel targeted therapies.
• Translate available and emerging clinical trial data and outcomes into clinically meaningful information for providing care to patients with SLE.
• Explain data about treatment options to patient with SLE.

Activity Description

Immerse yourself in this 60-minute interactive activity to meet a patient with systemic lupus erythematosus (SLE), view concise presentations, and engage in hands-on experience with the content. This activity will highlight the immunopathogenesis of SLE and mechanisms of action of therapies. Additionally, leading clinical experts will review clinical trial data and outcomes, both available and emerging, and translate them into clinically meaningful information for patient care. This activity is one of two in the series, Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Faculty

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

• Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD, and Megan Ragan
• Presenter: Lauren Irving

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Presenter: Sheetal Desai, MD, MSEd

• Advisory Board: Janssen, GlaxoSmithKline
• Speakers Bureau: Janssen, GlaxoSmithKline

Presenter: Bevra H. Hahn, MD

• Advisory Board: Janssen
• Consulting Fee: Aurinia
• Data Safety Monitoring: UCB

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

UEMS-EACCME^®: The UEMS-EACCME^® has an agreement of mutual recognition of AMA PRA Category 1 Credit(s)™. International physicians interested in converting AMA PRA Category 1 Credit(s)™ to EACCME credit should contact the UEMS, https://www.uems.eu/.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.